894 / 1851
CONCLUSION: High dose MTX-Cytarabine is the new standard
chemotherapeutic approach
PFS
OS
p = 0.07
p = 0.01
3 years OS:
46% vs 32%
3 years OS:
38% vs 21%
Ferreri AJ et al, Lancet 2009; 374
|
|
894 / 1851
CONCLUSION: High dose MTX-Cytarabine is the new standard
chemotherapeutic approach
PFS
OS
p = 0.07
p = 0.01
3 years OS:
46% vs 32%
3 years OS:
38% vs 21%
Ferreri AJ et al, Lancet 2009; 374